Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 18/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD5 | P21918 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1039551 | 0.84 | GRM2 (0.42) | GRM2MAPK14DRD2DRD1DRD4 | |
| SCHEMBL171794 | 0.82 | GRM2 (0.61) | GRM2 | |
| SCHEMBL2186985 | 0.77 | GRM2 (0.46) | GRM2MAPK14DRD2DRD1DRD4 | |
| SCHEMBL15180976 | 0.65 | P2RX3 (0.41) | MAPK14DRD2DRD1DRD4DRD5 | |
| SCHEMBL4381716 | 0.65 | MAPK14 (0.62) | MAPK14 | |
| SCHEMBL12074950 | 0.64 | DRD2 (0.33) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL28115604 | 0.63 | DRD2 (0.40) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL171728 | 0.62 | GRM2 (0.69) | GRM2 | |
| SCHEMBL16895310 | 0.62 | SMN1; SMN2 (0.49) | — | |
| SCHEMBL20540002 | 0.62 | DRD2 (0.44) | DRD2DRD1DRD4DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346505-B1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2346505-B1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8697689-B2 | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275624-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. | 2011-11-10 | — | — | US | disclosed |
| US-20110275624-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. | 2011-11-10 | — | — | US | disclosed |
| US-20110275624-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. | 2011-11-10 | — | — | US | disclosed |
| EP-2346505-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010043396-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043396-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275624-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM2, GRM1, GRM5 | GRM2 1/4885MAPK14 2235/4885DRD2 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.